Arrakis is discovering and developing small molecule therapeutics that target RNA with an internal product pipeline focused on neurology, oncology, and rare genetic disorders. The basis of Arrakis’ unique approach is comprised of a high-throughput, comprehensive system of bioinformatics tools and a proprietary chemical biology technology that interrogates structures of folded RNAs in their native state, within cells, to enable discovery and rational design of potent, selective small-molecule inhibitors of RNA function.